Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Vermillion’s biomarker panel study shows PAD diagnosis benefits

Vermillion : 09 April, 2008  (Company News)
Vermillion has presented data from a study providing further confirmation that the company's multi-protein biomarker panel may aid in the diagnosis of peripheral artery disease (PAD
The research suggests that such a panel may be useful in alerting physicians to the possibility of PAD in patients who might otherwise be undiagnosed. Results of the study were presented as a poster at the American College of Cardiology 57th Annual Scientific Session.

Working in collaboration with researchers at Stanford University, Vermillion intends to develop a blood test for the diagnosis of PAD. In March 2008, the company entered into an exclusive license agreement with the University to develop and commercialise a Biomarker panel used to assess the risk of the disease, which is estimated to affect up to 12 million Americans and can result in severe complications, including amputation, heart attack, stroke and even death.

'Few studies have explored combinations of protein markers to create a distinct Biomarker panel score to stratify individuals according to their risk of having PAD. However, our study successfully accomplishes this by discovering a multi-marker panel that could significantly aid in identifying such patients,' said Eric T Fung, MD, PhD, chief scientific officer of Vermillion. 'We are pleased with these findings and are developing a clinical trial protocol to generate data for support of a submission to the US Food and Drug Administration (FDA).'

The study was conducted to develop an index score based on a combination of proposed biomarkers for PAD, including two based on proteomic discovery. A total of 540 patients were analysed in the study. These patients were randomly selected from the ongoing GenePAD trial, which comprises individuals undergoing coronary angiography at Stanford University or Mount Sinai Medical Centers.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo